Fabiyola Selvaraj

Fabiyola Selvaraj began their work experience in 1999 as a Research Scientist at RiboMed Biotechnologies, Inc., where they worked until 2005. In this role, they conducted research and contributed to the development of scientific assays.

In 2009, they returned to RiboMed Biotechnologies, Inc. as a Research Scientist. During this time, they developed an assay to detect CpG methylation status in the BRCA1 gene using Ribomed's CAPS technology. Fabiyola also transferred a detection method from HPLC-MS/MS to a FRET-based fluorescent method.

In 2011, they joined Prometheus Laboratories Inc., A Nestlé Health Science Company as a Research Scientist II. Fabiyola'swork focused on new product development, particularly in the area of gastrointestinal diseases and disorders. As a Team Lead, they participated in the discovery and assay development of pathway-specific biomarkers. Fabiyola also led a cross-functional team for the design of sample collection and transport for the IBcause™ product.

In 2013, Fabiyola was promoted to Senior Research Scientist I at Prometheus Laboratories Inc. Fabiyola continued to contribute to new product development and led a team in their role.

In 2014, they took on the role of Senior Research Scientist II at Prometheus Laboratories Inc. Fabiyola remained involved in new product development and also led a cross-functional team for kit design.

In 2018, Fabiyola worked briefly as a Principal Scientist at Precision IBD.

Overall, Fabiyola Selvaraj has gained extensive experience in research and development and has held various roles in the biotechnology industry. Fabiyola has led teams, contributed to the development of scientific assays, and focused on product development in areas such as gastrointestinal diseases and disorders.

Fabiyola Selvaraj obtained a Ph.D. in Chemistry and Biochemistry from Arizona State University in 1999.